Condition: Ulcerative Colitis · Sponsor: Sanofi
This is a phase 2b, randomized, double-blind, 3-arm study for the treatment of Ulcerative Colitis. The primary objective of this study is to assess the efficacy of different doses of SAR442970 compared with placebo in participants with moderate to severe Ulcerative Colitis. The total study duration is up to 168 weeks, with a treatment period of up to 158 weeks including an open-label (OL) long-term extension (LTE) period of up to 104 weeks for eligible participants.
This description comes directly from the study's public registry record.
Trial Transparency email recommended (Toll free for US & Canada) · 800-633-1610 · contact-us@sanofi.com
Always discuss trial participation with your own doctor first.
| Investigational Site Number: 8400009 | Escondido, California, United States | Recruiting |
| Investigational Site Number: 8400006 | Lancaster, California, United States | Recruiting |
| Investigational Site Number: 8400025 | Thousand Oaks, California, United States | Recruiting |
| Investigational Site Number: 8400024 | Jacksonville, Florida, United States | Recruiting |
| Investigational Site Number: 8400030 | Kissimmee, Florida, United States | Recruiting |
| Investigational Site Number: 8400003 | Lighthouse PT, Florida, United States | Recruiting |
| Investigational Site Number: 8400001 | Miami, Florida, United States | Recruiting |
| Investigational Site Number: 8400011 | Miami, Florida, United States | Recruiting |
| Investigational Site Number: 8400010 | Palmetto Bay, Florida, United States | Recruiting |
| Investigational Site Number: 8400019 | Tampa, Florida, United States | Recruiting |
| Investigational Site Number: 8400018 | Marietta, Georgia, United States | Recruiting |
| Investigational Site Number: 8400005 | Iowa City, Iowa, United States | Recruiting |
+ 55 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06975722